Akari Therapeutics Plc (AKTX) Q4 2024 Earnings Report

Executive summary: Akari Therapeutics reported a Q4 2024 net loss of $3.77 million on a backdrop of zero revenue, underscored by meaningful R&D and SG&A spend and a continued reliance on financing to support operations. Operating loss for the quarter was $5.28 million with EBITDA of -$3.65 million, driven primarily by ongoing R&D intensity and administrative costs typical of a clinical-stage biotechnology company in late-stage preclinical or early clinical phases without product revenue.

Balance sheet and liquidity remained tight. Cash and cash equivalents stood at approximately $2.66 million at 2024-12-31, with net debt marginally negative ($0.66 million) after a $2.15 million inflow from financing activities and a $2.12 million operating cash outflow. The company carries a very low current ratio (0.148) and relies on periodic equity financing to fund its burn, evidenced by common stock issuances of about $3.13 million in the period. Intangible assets (~$39.18 million) and goodwill (~$8.43 million) comprise a substantial portion of total assets ($50.56 million), highlighting a heavy upfront investment in pipeline assets rather than near-term revenue generation. The quarterly and annual trends show widening operating losses with only limited visibility on revenue milestones in the near term, suggesting a heightened need for strategic partnerships or regulatory milestones to unlock value.

Looking ahead, the absence of formal forward guidance in the QQ4 2024 data requires investors to focus on pipeline catalysts, potential licensing deals for nomacopan, and the management’s ability to extend the company’s cash runway through non-dilutive or dilutive financing. Given the current burn rate, financing needs and clinical milestones will be key drivers of stock performance and equity risk.